{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T06:49:02Z","timestamp":1774939742575,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Definitive chemoradiotherapy (CRT) is standard of care for nasopharyngeal carcinoma. Due to the tumor localization and concomitant platinum-based chemotherapy, hearing impairment is a frequent complication, without defined dose-threshold. In this study, we aimed to achieve the maximum possible cochleae sparing.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Materials and methods<\/jats:title>\n                <jats:p>Treatment plans of 20 patients, treated with CRT (6 IMRT and 14 VMAT) based on the QUANTEC organs-at-risk constraints were investigated. The cochleae were re-delineated independently by two radiation oncologists, whereas target volumes and other organs at risk (OARs) were not changed. The initial plans, aiming to a mean cochlea dose &lt;\u200945\u00a0Gy, were re-optimized with VMAT, using 2\u20132.5 arcs without compromising the dose coverage of the target volume. Mean cochlea dose, PTV coverage, Homogeneity Index, Conformity Index and dose to other OAR were compared to the reference plans. Wilcoxon signed-rank test was used to evaluate differences, a <jats:italic>p <\/jats:italic>value &lt;\u20090.05 was considered significant.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The re-optimized plans achieved a statistically significant lower dose for both cochleae (median dose for left and right 14.97\u00a0Gy and 18.47\u00a0Gy vs. 24.09\u00a0Gy and 26.05\u00a0Gy respectively, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) compared to the reference plans, without compromising other plan quality parameters. The median NTCP for tinnitus of the most exposed sites was 11.3% (range 3.52\u201391.1%) for the original plans, compared to 4.60% (range 1.46\u201390.1%) for the re-optimized plans (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). For hearing loss, the median NTCP of the most exposed sites could be improved from 0.03% (range 0\u201399.0%) to 0.00% (range 0\u201398.5%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>A significantly improved cochlea sparing beyond current QUANTEC constraints is feasible without compromising the PTV dose coverage in nasopharyngeal carcinoma patients treated with VMAT. As there appears to be no threshold for hearing toxicity after CRT, this should be considered for future treatment planning.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13014-021-01796-4","type":"journal-article","created":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T21:02:26Z","timestamp":1617310946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Cochlea sparing optimized radiotherapy for nasopharyngeal carcinoma"],"prefix":"10.1186","volume":"16","author":[{"given":"Enkelejda","family":"Lamaj","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erwin","family":"Vu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Janita E.","family":"van Timmeren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Leonardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Louise","family":"Marc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izabela","family":"Pytko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Guckenberger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5261-6446","authenticated-orcid":false,"given":"Panagiotis","family":"Balermpas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,1]]},"reference":[{"key":"1796_CR1","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.radonc.2014.02.003","volume":"110","author":"AWM Lee","year":"2014","unstructured":"Lee AWM, Ng WT, Chan LLK, Hung WM, Chan CCC, Sze HCK, et al. Evolution of treatment for nasopharyngeal cancer\u2014success and setback in the intensity-modulated radiotherapy era. RadiotherOncol. 2014;110:377\u201384. https:\/\/doi.org\/10.1016\/j.radonc.2014.02.003.","journal-title":"RadiotherOncol"},{"key":"1796_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/bjc.2013.720","volume":"110","author":"L Zeng","year":"2014","unstructured":"Zeng L, Tian Y-M, Sun X-M, Chen C-Y, Han F, Xiao W-W, et al. Late toxicities after intensity-modulated radiotherapy for nasopharyngeal carcinoma: patient and treatment-related risk factors. Br J Cancer. 2014;110:49\u201354. https:\/\/doi.org\/10.1038\/bjc.2013.720.","journal-title":"Br J Cancer"},{"key":"1796_CR3","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s00066-017-1205-y","volume":"193","author":"S Scobioala","year":"2017","unstructured":"Scobioala S, Parfitt R, Matulat P, Kittel C, Ebrahimi F, Wolters H, et al. Impact of radiation technique, radiation fraction dose, and total cisplatin dose on hearing: retrospective analysis of 29 medulloblastoma patients. StrahlentherOnkol. 2017;193:910\u201320. https:\/\/doi.org\/10.1007\/s00066-017-1205-y.","journal-title":"StrahlentherOnkol"},{"key":"1796_CR4","doi-asserted-by":"publisher","first-page":"S50","DOI":"10.1016\/j.ijrobp.2009.04.096","volume":"76","author":"N Bhandare","year":"2010","unstructured":"Bhandare N, Jackson A, Eisbruch A, Pan CC, Flickinger JC, Antonelli P, et al. Radiation therapy and hearing loss. Int J RadiatOncol. 2010;76:S50\u20137. https:\/\/doi.org\/10.1016\/j.ijrobp.2009.04.096.","journal-title":"Int J RadiatOncol"},{"key":"1796_CR5","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.ijrobp.2004.08.019","volume":"61","author":"CC Pan","year":"2005","unstructured":"Pan CC, Eisbruch A, Lee JS, Snorrason RM, Ten Haken RK, Kileny PR. Prospective study of inner ear radiation dose and hearing loss in head-and-neck cancer patients. Int J RadiatOncol. 2005;61:1393\u2013402. https:\/\/doi.org\/10.1016\/j.ijrobp.2004.08.019.","journal-title":"Int J RadiatOncol"},{"key":"1796_CR6","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.tranon.2015.10.003","volume":"8","author":"J Wang","year":"2015","unstructured":"Wang J, Chen Y-Y, Tai A, Chen X-L, Huang S-M, Yang C, et al. Sensorineural hearing loss after combined intensity modulated radiation therapy and cisplatin-based chemotherapy for nasopharyngeal carcinoma. TranslOncol. 2015;8:456\u201362. https:\/\/doi.org\/10.1016\/j.tranon.2015.10.003.","journal-title":"TranslOncol"},{"key":"1796_CR7","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/s00066-011-2170-5","volume":"187","author":"BA Jereczek-Fossa","year":"2011","unstructured":"Jereczek-Fossa BA, Rondi E, Zarowski A, D\u2019Onofrio A, Alterio D, Ciocca M, et al. Prospective study on the dose distribution to the acoustic structures during postoperative 3D conformal radiotherapy for parotid tumors: Dosimetric and audiometric aspects. StrahlentherOnkol. 2011;187:350\u20136. https:\/\/doi.org\/10.1007\/s00066-011-2170-5.","journal-title":"StrahlentherOnkol"},{"key":"1796_CR8","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1002\/hed.20426","volume":"28","author":"L van der Putten","year":"2006","unstructured":"van der Putten L, de Bree R, Plukker JT, Langendijk JA, Smits C, Burlage FR, et al. Permanent unilateral hearing loss after radiotherapy for parotid gland tumors. Head Neck. 2006;28:902\u20138. https:\/\/doi.org\/10.1002\/hed.20426.","journal-title":"Head Neck"},{"key":"1796_CR9","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.radonc.2017.10.032","volume":"126","author":"AW Lee","year":"2018","unstructured":"Lee AW, Ng WT, Pan JJ, Poh SS, Ahn YC, AlHussain H, et al. International guideline for the delineation of the clinical target volumes (CTV) for nasopharyngeal carcinoma. RadiotherOncol. 2018;126:25\u201336. https:\/\/doi.org\/10.1016\/j.radonc.2017.10.032.","journal-title":"RadiotherOncol"},{"key":"1796_CR10","doi-asserted-by":"publisher","first-page":"3684","DOI":"10.1200\/JCO.2008.19.9109","volume":"27","author":"N Lee","year":"2009","unstructured":"Lee N, Harris J, Garden AS, Straube W, Glisson B, Xia P, et al. Intensity-modulated radiation therapy with or without chemotherapy for nasopharyngeal carcinoma: radiation therapy oncology group phase II trial 0225. J ClinOncol. 2009;27:3684\u201390. https:\/\/doi.org\/10.1200\/JCO.2008.19.9109.","journal-title":"J ClinOncol"},{"key":"1796_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.radonc.2015.07.041","volume":"117","author":"CL Brouwer","year":"2015","unstructured":"Brouwer CL, Steenbakkers RJHM, Bourhis J, Budach W, Grau C, Gr\u00e9goire V, et al. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. RadiotherOncol. 2015;117:83\u201390. https:\/\/doi.org\/10.1016\/j.radonc.2015.07.041.","journal-title":"RadiotherOncol"},{"key":"1796_CR12","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1016\/j.ijrobp.2005.09.028","volume":"64","author":"L Feuvret","year":"2006","unstructured":"Feuvret L, No\u00ebl G, Mazeron J-J, Bey P. Conformity index: a review. Int J RadiatOncol. 2006;64:333\u201342. https:\/\/doi.org\/10.1016\/j.ijrobp.2005.09.028.","journal-title":"Int J RadiatOncol"},{"key":"1796_CR13","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/s13014-015-0501-x","volume":"10","author":"T-F Lee","year":"2015","unstructured":"Lee T-F, Yeh S-A, Chao P-J, Chang L, Chiu C-L, Ting H-M, et al. Normal tissue complication probability modeling for cochlea constraints to avoid causing tinnitus after head-and-neck intensity-modulated radiation therapy. RadiatOncol. 2015;10:194. https:\/\/doi.org\/10.1186\/s13014-015-0501-x.","journal-title":"RadiatOncol"},{"key":"1796_CR14","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1080\/09553002.2017.1385872","volume":"93","author":"S Cheraghi","year":"2017","unstructured":"Cheraghi S, Nikoofar A, Bakhshandeh M, Khoei S, Farahani S, Abdollahi H, et al. Normal tissue complication probability modeling of radiation-induced sensorineural hearing loss after head-and-neck radiation therapy. Int J RadiatBiol. 2017;93:1327\u201333. https:\/\/doi.org\/10.1080\/09553002.2017.1385872.","journal-title":"Int J RadiatBiol"},{"key":"1796_CR15","doi-asserted-by":"publisher","first-page":"20140413","DOI":"10.1259\/bjr.20140413","volume":"88","author":"L De Marzi","year":"2015","unstructured":"De Marzi L, Feuvret L, Boul\u00e9 T, Habrand J-L, Martin F, Calugaru V, et al. Use of gEUD for predicting ear and pituitary gland damage following proton and photon radiation therapy. Br J Radiol. 2015;88:20140413. https:\/\/doi.org\/10.1259\/bjr.20140413.","journal-title":"Br J Radiol"},{"key":"1796_CR16","doi-asserted-by":"publisher","first-page":"e145","DOI":"10.1016\/j.prro.2016.11.003","volume":"7","author":"IJ Das","year":"2017","unstructured":"Das IJ, Andersen A, Chen Z, Dimofte A, Glatstein E, Hoisak J, et al. State of dose prescription and compliance to international standard (ICRU-83) in intensity modulated radiation therapy among academic institutions. PractRadiatOncol. 2017;7:e145\u201355. https:\/\/doi.org\/10.1016\/j.prro.2016.11.003.","journal-title":"PractRadiatOncol"},{"key":"1796_CR17","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1097\/01.coc.0000143847.57027.16","volume":"28","author":"HD Pacholke","year":"2005","unstructured":"Pacholke HD, Amdur RJ, Schmalfuss IM, Louis D, Mendenhall WM. Contouring the middle and inner ear on radiotherapy planning scans. Am J ClinOncol. 2005;28:143\u20137. https:\/\/doi.org\/10.1097\/01.coc.0000143847.57027.16.","journal-title":"Am J ClinOncol"},{"key":"1796_CR18","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1016\/0360-3016(91)90030-8","volume":"20","author":"SA Leibel","year":"1991","unstructured":"Leibel SA, Kutcher GJ, Harrison LB, Fass DE, Burman CM, Hunt MA, et al. Improved dose distributions for 3d conformal boost treatments in carcinoma of the nasopharynx. Int J RadiatOncol. 1991;20:823\u201333. https:\/\/doi.org\/10.1016\/0360-3016(91)90030-8.","journal-title":"Int J RadiatOncol"},{"key":"1796_CR19","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/S0360-3016(00)01588-1","volume":"49","author":"SL Wolden","year":"2001","unstructured":"Wolden SL, Zelefsky MJ, Hunt MA, Rosenzweig KE, Chong LM, Kraus DH, et al. Failure of a 3D conformal boost to improve radiotherapy for nasopharyngeal carcinoma. Int J RadiatOncol. 2001;49:1229\u201334. https:\/\/doi.org\/10.1016\/S0360-3016(00)01588-1.","journal-title":"Int J RadiatOncol"},{"key":"1796_CR20","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.3171\/2011.7.JNS11749","volume":"115","author":"T Hasegawa","year":"2011","unstructured":"Hasegawa T, Kida Y, Kato T, Iizuka H, Yamamoto T. Factors associated with hearing preservation after Gamma Knife surgery for vestibular schwannomas in patients who retain serviceable hearing. J Neurosurg. 2011;115:1078\u201386. https:\/\/doi.org\/10.3171\/2011.7.JNS11749.","journal-title":"J Neurosurg"},{"key":"1796_CR21","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/(sici)1097-0347(199909)21:6<547::aid-hed8>3.0.co;2-y","volume":"21","author":"WK Ho","year":"1999","unstructured":"Ho WK, Wei WI, Kwong DL, Sham JS, Tai PT, Yuen AP, et al. Long-term sensorineural hearing deficit following radiotherapy in patients suffering from nasopharyngeal carcinoma: a prospective study. Head Neck. 1999;21:547\u201353. https:\/\/doi.org\/10.1002\/(sici)1097-0347(199909)21:6%3c547::aid-hed8%3e3.0.co;2-y.","journal-title":"Head Neck"},{"key":"1796_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0167-8140(02)00211-6","volume":"65","author":"E Raaijmakers","year":"2002","unstructured":"Raaijmakers E, Engelen AM. Issensorineural hearing loss a possible side effect of nasopharyngeal and parotid irradiation? A systematic review of the literature. RadiotherOncol. 2002;65:1\u20137. https:\/\/doi.org\/10.1016\/S0167-8140(02)00211-6.","journal-title":"RadiotherOncol"},{"key":"1796_CR23","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1002\/hed.23201","volume":"35","author":"M Mujica-Mota","year":"2013","unstructured":"Mujica-Mota M, Waissbluth S, Daniel SJ. Characteristics of radiation-induced sensorineural hearing loss in head and neck cancer: a systematic review: Radiation-Induced Sensorineural Hearing Loss in Head and Neck Cancer. Head Neck. 2013;35:1662\u20138. https:\/\/doi.org\/10.1002\/hed.23201.","journal-title":"Head Neck"},{"key":"1796_CR24","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/0360-3016(91)90692-W","volume":"21","author":"C Grau","year":"1991","unstructured":"Grau C, Moller K, Overgaard M, Overgaard J, Elbrond O. Sensori-neural hearing loss in patients treated with irradiation for nasopharyngeal carcinoma. Int J RadiatOncol. 1991;21:723\u20138. https:\/\/doi.org\/10.1016\/0360-3016(91)90692-W.","journal-title":"Int J RadiatOncol"},{"key":"1796_CR25","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.ijrobp.2006.09.017","volume":"67","author":"N Bhandare","year":"2007","unstructured":"Bhandare N, Antonelli PJ, Morris CG, Malayapa RS, Mendenhall WM. Ototoxicity after radiotherapy for head and neck tumors. Int J RadiatOncol. 2007;67:469\u201379. https:\/\/doi.org\/10.1016\/j.ijrobp.2006.09.017.","journal-title":"Int J RadiatOncol"},{"key":"1796_CR26","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/j.ijrobp.2008.07.034","volume":"73","author":"SH Chan","year":"2009","unstructured":"Chan SH, Ng WT, Kam KL, Lee MCH, Choi CW, Yau TK, et al. Sensorineural hearing loss after treatment of nasopharyngeal carcinoma: a longitudinal analysis. Int J RadiatOncol. 2009;73:1335\u201342. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.07.034.","journal-title":"Int J RadiatOncol"},{"key":"1796_CR27","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.oraloncology.2018.08.018","volume":"86","author":"NP Brodin","year":"2018","unstructured":"Brodin NP, Tom\u00e9 WA. Revisiting the dose constraints for head and neck OARs in the current era of IMRT. Oral Oncol. 2018;86:8\u201318. https:\/\/doi.org\/10.1016\/j.oraloncology.2018.08.018.","journal-title":"Oral Oncol"},{"key":"1796_CR28","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.radonc.2012.11.013","volume":"106","author":"T-F Lee","year":"2013","unstructured":"Lee T-F, Fang F-M. Quantitative analysis of normal tissue effects in the clinic (QUANTEC) guideline validation using quality of life questionnaire datasets for parotid gland constraints to avoid causing xerostomia during head-and-neck radiotherapy. RadiotherOncol. 2013;106:352\u20138. https:\/\/doi.org\/10.1016\/j.radonc.2012.11.013.","journal-title":"RadiotherOncol"},{"key":"1796_CR29","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.radonc.2012.08.013","volume":"104","author":"G Peng","year":"2012","unstructured":"Peng G, Wang T, Yang K, Zhang S, Zhang T, Li Q, et al. A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. RadiotherOncol. 2012;104:286\u201393. https:\/\/doi.org\/10.1016\/j.radonc.2012.08.013.","journal-title":"RadiotherOncol"},{"key":"1796_CR30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.ejca.2018.08.006","volume":"103","author":"CM Nutting","year":"2018","unstructured":"Nutting CM, Morden JP, Beasley M, Bhide S, Cook A, De Winton E, et al. Results of a multicentre randomised controlled trial of cochlear-sparing intensity-modulated radiotherapy versus conventional radiotherapy in patients with parotid cancer (COSTAR; CRUK\/08\/004). Eur J Cancer. 2018;103:249\u201358. https:\/\/doi.org\/10.1016\/j.ejca.2018.08.006.","journal-title":"Eur J Cancer"},{"key":"1796_CR31","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2822","author":"JK Bass","year":"2020","unstructured":"Bass JK, Liu W, Banerjee P, Brinkman TM, Mulrooney DA, Gajjar A, et al. Association of hearing impairment with neurocognition in survivors of childhood cancer. JAMA Oncol. 2020. https:\/\/doi.org\/10.1001\/jamaoncol.2020.2822.","journal-title":"JAMA Oncol"},{"key":"1796_CR32","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1007\/s00066-018-1344-9","volume":"194","author":"LH Braun","year":"2018","unstructured":"Braun LH, Braun K, Frey B, Wolpert SM, L\u00f6wenheim H, Zips D, et al. Unilateral cochlea sparing in locoregionally advanced head and neck cancer: a planning study. StrahlentherOnkol. 2018;194:1124\u201331. https:\/\/doi.org\/10.1007\/s00066-018-1344-9.","journal-title":"StrahlentherOnkol"},{"key":"1796_CR33","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.meddos.2018.08.003","volume":"44","author":"C Zhang","year":"2019","unstructured":"Zhang C, Liu L, Li W, Liang W, Chen Z, Huang X, et al. Cochlea sparing with a stratified scheme of dose limitation employed in intensity-modulated radiotherapy for nasopharyngeal carcinoma: a dosimetry study. Med Dosim. 2019;44:226\u201332. https:\/\/doi.org\/10.1016\/j.meddos.2018.08.003.","journal-title":"Med Dosim"},{"key":"1796_CR34","doi-asserted-by":"publisher","first-page":"20150052","DOI":"10.1259\/bjr.20150052","volume":"88","author":"J Gao","year":"2015","unstructured":"Gao J, Qian T-L, Tao C-Z, Zhang Y-H, Zhou Y, Yang J, et al. SmartArc-based volumetric modulated arc therapy can improve the middle ear, vestibule and cochlea sparing for locoregionally advanced nasopharyngeal carcinoma: a dosimetric comparison with step-and-shoot intensity-modulated radiotherapy. Br J Radiol. 2015;88:20150052. https:\/\/doi.org\/10.1259\/bjr.20150052.","journal-title":"Br J Radiol"},{"key":"1796_CR35","doi-asserted-by":"publisher","DOI":"10.1700\/1217.13493","author":"NP Nguyen","year":"2012","unstructured":"Nguyen NP, Ceizyk M, Vinh-Hung V, Sroka T, Jang S, Khan R, et al. Feasibility of tomotherapy to reduce cochlea radiation dose in patients with locally advanced nasopharyngeal cancer. Tumori. 2012. https:\/\/doi.org\/10.1700\/1217.13493.","journal-title":"Tumori"},{"key":"1796_CR36","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2019.07.007","volume":"119","author":"Q Yang","year":"2019","unstructured":"Yang Q, Cao S-M, Guo L, Hua Y-J, Huang P-Y, Zhang X-L, et al. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Eur J Cancer. 2019;119:87\u201396. https:\/\/doi.org\/10.1016\/j.ejca.2019.07.007.","journal-title":"Eur J Cancer"},{"key":"1796_CR37","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1056\/NEJMoa1905287","volume":"381","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Chen L, Hu G-Q, Zhang N, Zhu X-D, Yang K-Y, et al. Gemcitabine and cisplatin induction chemotherapy in nasopharyngeal carcinoma. N Engl J Med. 2019;381:1124\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1905287.","journal-title":"N Engl J Med"},{"key":"1796_CR38","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1200\/JCO.2016.67.4119","volume":"35","author":"L Ribassin-Majed","year":"2017","unstructured":"Ribassin-Majed L, Marguet S, Lee AWM, Ng WT, Ma J, Chan ATC, et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J ClinOncol. 2017;35:498\u2013505. https:\/\/doi.org\/10.1200\/JCO.2016.67.4119.","journal-title":"J ClinOncol"},{"key":"1796_CR39","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1016\/j.ijrobp.2008.05.040","volume":"73","author":"YJ Hitchcock","year":"2009","unstructured":"Hitchcock YJ, Tward JD, Szabo A, Bentz BG, Shrieve DC. Relative contributions of radiation and cisplatin-based chemotherapy to sensorineural hearing loss in head-and-neck cancer patients. Int J RadiatOncol. 2009;73:779\u201388. https:\/\/doi.org\/10.1016\/j.ijrobp.2008.05.040.","journal-title":"Int J RadiatOncol"},{"key":"1796_CR40","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ejmp.2019.04.003","volume":"61","author":"MA Mosleh-Shirazi","year":"2019","unstructured":"Mosleh-Shirazi MA, Amraee A, Mohaghegh F. Dose-response relationship and normal-tissue complication probability of conductive hearing loss in patients undergoing head-and-neck or cranial radiotherapy: a prospective study including 70 ears. Phys Med. 2019;61:64\u20139. https:\/\/doi.org\/10.1016\/j.ejmp.2019.04.003.","journal-title":"Phys Med"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-021-01796-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13014-021-01796-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-021-01796-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T21:02:29Z","timestamp":1617310949000},"score":1,"resource":{"primary":{"URL":"https:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-021-01796-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1796"],"URL":"https:\/\/doi.org\/10.1186\/s13014-021-01796-4","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,1]]},"assertion":[{"value":"1 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Every patient consented to anonymous data collection and the retrospective evaluation of patient and treatment data was approved by the local ethics committee (ProjectID 2019-00684).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"All authors proof-read, edited, approved the final manuscript and provided their consent for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}